Make an enquiry
Refer a patient
HCP Logout

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor
Make an enquiry
Refer a patient

We noticed you are on our AU page. Want to switch regions? Choose from the options:

UK
ES
Find a centre
Find a doctor

Prostate Cancer

Prostate Cancer
2025-06-03T00:00:00.000+10:00
Ongoing

CA071-1000

CA071-1000
Prostate

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

A Phase 3, Two-part, Randomized, Open-label, Adaptive Study Comparing BMS-986365 versus a Second Androgen Receptor Pathway Inhibitor (ARPI), in Participants with Metastatic Castration-Resistant Prostate Cancer (mCRPC).

Trial overview

Clinical Area

Medical Oncology

Disease

Prostate

Disease site

Genitourinary (GU)

Study Phase

III

Trial Identifiers

Registration number: NCT06764485

https://clinicaltrials.gov/study/NCT06764485

GenesisCare Location(s)
Principal Investigator(s)
Medical Oncologist

Dr Felicia Roncolato

MBChB FRACP MMed (Clin Epi) PhD

Dr Felicia Roncolato
location pin icon

Campbelltown (Oncology)

View Profile
Profile Image - Dr Felicia Roncolato

Clinical trials enquiries

Thank you for submitting.

We will be in touch within 24 hours

An unexpected error has occurred.

You will need to complete the form again, sorry for the inconvenience.

How can we help?

If you have a medical emergency please call 000. If you have an urgent request and would like to speak to our staff, please contact one of our centres directly.

* Indicates a required field.


 

Disclaimer:

This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.